NewsIs CBD A Boom-Or-Bust Fad - Or A Major...

Is CBD A Boom-Or-Bust Fad – Or A Major FMCG Opportunity?


SUGGESTIONS that CBD is a fad – a boom-to-bust market – with the latter imminent, raised a few eyebrows at Cannabis Europa

In an occasionally feisty discussion panel host Prohibition Partners’ CEO and co-founder Stephen Murphy, challenged CBD entrepreneur Clifton Flack, founder of UK firm CiiTECH.

“Is CBD all about the hype? It is accessible, it’s easily available, it’s easy to set up a business, to secure a white-label product and launch a website 

“There are low barriers to entry, there are questions around brands, around the supply chain and efficacy. Is CBD here to stay, or has it peaked?”

No-One Buys CBD For Fun

“Its booming,” retorted Mr Flack. “There are low barriers to entry in CBD but the same can be said about medical cannabis – a company can promise to be the best cultivator, secure millions of investment and not deliver on revenues for years.

“What both lack is a business; a brand that sells, that can demonstrate a track record of sales and revenues.”

Clifton Flack

Mr Flack’s company CiiTECH launched its Provacan range five years ago and as such has the data, sales and track record which convinced investors to support its pre-IPO, LSE fundraise earlier this year.

He recently rebranded the company as a ‘Cannabis Healthcare’ brand saying: “No one buys CBD for fun – only for health benefits.”

Mr Flack believes that as the cannabis market matures the key to success will be the emergence of brands and the ‘convergence ‘of the CBD and THC brands and markets, saying CiiTECH aims to be to the fore in this regard.

“The THC market is all about cultivation, and extraction. The brand is neglected under the mistaken belief that cultivation equals sales.

“As we move to launch our THC brands in Israel we will be working with the best of the best, and aiming to build a leading brand.”

Institutions Still Wary

Kingsley Wilson, Co-Founder of Chrystal Capital Partners, an investor in CiiTECH, said there is still no appetite in the institutional capital market for cannabis due to the issues with compliance.

He said the key to backing CBD brands included finding the right management team, and he highlighted that a common fatuous approach from many players in the industry is to say ‘we are about to IPO, and will be acquired next year’.

He believes the CBD industry may be at the ‘end of the beginning’ and we may be in for a process of consolidation in the market which could provide opportunities for private equity.

Stanton McLean, the Advisory Director of Artemis Growth Partners, came to cannabis through personal CBD use and highlighted the need to support greater consumer education in the market. He also believes the institutional investors continue to be wary of the space due to compliance concerns.

Cannabis Europa, organised by Prohibition Partners, took place at Central London’s Banking Hall yesterday and Wednesday with a host of leading speakers and attendees. 

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


Please enter your comment!
Please enter your name here

Latest news

High-Profile Director Quits Oxford Cannabinoid Technologies Board Following Chairman’s Recent Departure

Oxford Cannabinoid Technologies (OCT) has seen its second senior departure in under a month as it begins to recover...

Columbia Care Platinum Joins Forces With Poppy Jamie

Leading organic, vegan and regeneratively-farmed, plant-based CBD brand, Columbia Care Platinum(, announces it has teamed up with Poppy Jamie, mental wellbeing...

InterCure Announces European Expansion with International Cannabis Brand Cookies

InterCure Ltd. today announced its international expansion into Europe through a partnership with iconic cannabis brand Cookies. The parties entered...

Groups From 56 Countries Ask UN To Ensure Secretive ‘Cannabis Initiative’ Is Open To Public Scrutiny

ONE year on from the formal recognition of the potential for cannabis as a medicine almost 200 global advocacy...

The New Common Agricultural Policy Has Been Adopted And the Maximum THC Level on the Field Has Been Restored to 0.3%

It was in October 2020 when we announced that the European Parliament had voted in favour of restoring the...

European Medical Cannabis Tech Accelerator Opens Call for Submissions

The first and only hybrid tech accelerator in Europe dedicated to the medical cannabis industry offers €100,000 grant to early-stage startups from around the world.

Must read

High-Profile Director Quits Oxford Cannabinoid Technologies Board Following Chairman’s Recent Departure

Oxford Cannabinoid Technologies (OCT) has seen its second senior...

You might also likeRELATED
Recommended to you